ERBB2 and ovarian carcinoma: Furthermore, the in vivo delivery of the αHer‐CrNC into mice tumors of HER2‐positive ovarian cancer can induce dramatic suppression of tumor growth (80.3%), showing potential as an effective gene editing therapeutic for cancer treatment.